Table 1.
Analysis of measurements of Imatinib and 2nd-generation tyrosine kinase inhibitors Groups on day D-1
| Parameter | CML (n = 64) | Imatinib (n = 31) | 2nd-generation (n = 33) | p-value |
| Gender (male/female) | 34/30 | 16/15 | 18/15 | 0.5062 |
| Age (years) - mean ± SE | 45.30 ± 2.08 | 43.92 ± 2.99 | 46.63 ± 2.93 | 0.2609a |
| Age at diagnosis (years) - mean ± SE | 44.22 ± 2.01 | 41.64 ± 2.78 | 46.17 ± 2.80 | 0.1345a |
| Time since diagnosis (years) - mean ± SE | 7.755 ± 0.54 | 7.200 ± 0.99 | 8.778 ± 0.86 | 0.1296a |
| High Sokal risk - n (%) | 20 (31.2) | 5 (16.1) | 15 (44.5) | 0.0215b |
| Accelerated phase + blast crisis - n (%) | 27 (42.2) | 6 (19.5) | 21 (63.6) | 0.0014b |
| Nitrite (µM) - mean ± SE | 2.638 ± 0.327 | 2.010 ± 0.449 | 3.730 ± 0.429 | < 0.0001a |
| MDA (µM) - mean ± SE | 3.582 ± 0.306 | 2.818 ± 0.349 | 4.197 ± 0.445 | < 0.01a |
CML: chronic myeloid leukemia; MDA: malondialdehyde
a Student t-test; b Fisher's exact Test; statistically significance < 0.05